



Jack W. Britts Named Merz USA President & CEO

Former Sepracor & AstraZeneca Executive to Lead Growing Specialty Pharmaceutical Company

Merz Pharmaceuticals, LLC
For more information contact:
Kim Doran
336.544.2406
kdoran@quixotegroup.com

www.merzusa.com

GREENSBORO, NC, September 2008 – Jack Britts, an experienced pharmaceutical executive whose career includes senior roles at Sepracor Inc. and AstraZeneca PLC, has been named President and Chief Executive Officer (CEO) of Merz Pharmaceuticals, LLC.

In his new role, Britts will oversee further growth of Merz' current medical dermatology business and establish two new business units to support the company's robust product pipeline in aesthetics and neurology.

Merz Pharmaceuticals is the North American subsidiary of Merz GmbH & Co., a privately held pharmaceutical company recognized worldwide for the discovery and development of prescription and OTC products available to medical professionals and consumers in over 90 countries.

"Merz has grown nicely since its acquisition of Mayrand Pharmaceuticals more than a decade ago," Britts said. "We expect to leverage the experience and success of the US business and expand upon it by commercializing our portfolio of aesthetic and neurology products currently in development. We envision adding resources to medical affairs, sales, marketing, research and development and administrative functions to support our growth during this exciting phase of company expansion."

Prior to joining Merz, Britts spent 8 years at Sepracor Inc., a research-based pharmaceutical company focused on the treatment of respiratory and central nervous system (CNS) disorders, serving as Group Vice President in charge of commercial operations, where, among other product development activities, he was responsible for the commercialization of LUNESTA®.

From 1986 to 2000, Britts held various executive positions at AstraZeneca PLC, where he last served as Vice President, Therapeutic Area Leader Gastrointestinal Products, heading development of the US clinical, regulatory and commercial strategy for lifecycle management of the PPI portfolio, including Prilosec® and Nexium®. Britts' experience also includes an international assignment as General Manager for Zeneca businesses in Central and Eastern Europe, Turkey, the Middle East and Africa.



About Merz Pharmaceuticals:

A specialty pharmaceutical company, Merz Pharmaceuticals, LLC was established in 1995 and is responsible for the North American introduction of products developed within the global Merz organization. Specifically, Merz is dedicated to meeting unmet medical needs with innovative healthcare solutions that improve self-esteem and quality of life. Merz proudly distributes Naftin[®] (naftifine HCl 1%) and several non-prescription products, including Mederma[®] Skin Care for Scars[™], the #1 doctor- and pharmacist-recommended product for scars as well as new Mederma[®] Cream plus SPF 30 and Mederma[®] for Kids[™], the #1 pediatrician-recommended product for children's scars; Appearex[®], the #1 dermatologist-recommended product for strengthening nails; and Aqua Glycolic[®], an alpha hydroxy acid-based skin care system.

Globally, Merz is a leader in research and development of pharmaceuticals for the treatment of neurological disorders as well as for aesthetic dermatology, including best-in-class products for the treatment of wrinkles and aging skin, hair loss and acne. Merz also develops products to address the unmet needs of patients suffering from Alzheimer's, dystonias, and other debilitating neurological disorders.

For more information about Merz Pharmaceuticals, log onto www.merzusa.com.

###